Figure 2From: Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinomaAntiplatelets/NSAIDs are inversely associated with survival in HNSCC. A. Intake of these medications confers better outcomes in the general HNSCC patient population, B. The benefit associated with intake of antiplatelets/NSAIDs is particularly observed in the thrombocytosis group, HR = 0.42, p = 0.06. AP: Antiplatelets. ns: Not significant.Back to article page